Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with complex vascular abnormalities to be threat by a systemic therapy~* Patients must have adequate liver function (LDL-cholesterol, triglycerides,...)~* Patients must have adequate organ function: neutrophils \>1500/mm³, Hb \> 8,0 g et platelets\> 50.000/mm³ (no platelets limits for the Kasabach Merritt syndrome)~* Patients must have adequate renal function(normal creatinin depending on the age), clearance \> 70 ml/min/1.73m² and Urin Protein Creatinine ratio \<0.3 g.~* Karnofsky or Landry \> 50~Exclusion Criteria:~* Dental equipments or prosthesis interfering onto a radiological examen~* Other uncontrolled medical condition (uncontrolled diabetes, hypertension...)~* Concomitant drugs such as inhibitors/inducers of cytochrome P450 3A4 (CYP3A4)~* Immunocompromised patients, including known seropositivity for HIV~* Digestive problems modifying the absorption of Rapamycin (gastric tube feeding accepted)~* Pregnant or nursing (lactating) women~* Prior treatment with phosphatidylinositol 3-kinase (PI3K) and/or mTOR inhibitors

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).